Blueprint Medicines: 3Q Earnings Snapshot

November 5, 2019 GMT

CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Tuesday reported a loss of $94.3 million in its third quarter.

On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.93.

The results exceeded Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of $2.19 per share.

The cancer drug developer posted revenue of $9.1 million in the period, also exceeding Street forecasts. Six analysts surveyed by Zacks expected $3.7 million.

Blueprint Medicines shares have risen 25% since the beginning of the year. The stock has risen 2% in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC